Our research is focused on investigating the key pathophysiological mechanisms involved in the development of essential hypertension and associated renal complications. Hypertension has been characterized as one of the chronic pathological conditions of the human body and the exact mechanism of its development has not been identified yet, albeit various interlinking mechanisms have been studied and proposed. We demonstrated that chronic acidosis induction in animals could potentially lead to the activation of intrarenal renin angiotensin system and renal oxidative stress which eventually develops hypertensive state. We are now focused to investigate the potential biomarker that could possibly mediate the genesis of observed hypertension during acidotic conditions. This may elucidate a different origin for hypertension and may provide novel therapeutic targets for its treatment.

His current research aims to delineate the role of exosomes-associated cargo bioactive molecules as a trojan horse in altering oncologic pathways in tumor and stromal cells to promote cancer progression and metastasis using tissue culture, preclinical model, and human specimens. The findings from his research are of great asset to have successfully competed for NIH support. The ultimate goal of his ongoing research is to utilize different therapeutic strategies for reducing drug resistance and improving the survival of patients with malignant diseases such as prostate cancer and melanoma. One of these strategies is to elucidate the underlying molecular mechanisms of aggressive phenotypes of tumors and discover specific and efficient therapeutic targets. In the same context, there is a critical need for the discovery of novel and reliable biomarkers that can stratify cancer patients according to their pathological stages, response to certain therapeutics, tumor relapse and other clinical outcomes.